Actelion UK appoints Robin Bhattacherjee General Manager
pharmafile | November 4, 2009 | Appointment | Research and Development, Sales and Marketing | Actelion, appointment, research and development, sales and marketing
Actelion UK has appointed Robin Bhattacherjee general manager for the UK and Ireland. He will be based at the company’s UK office in Chiswick, London.
Prior to this role, Robin was executive director at CV Therapeutics (CVT) Europe where he was responsible for establishing the European office for CV Therapeutics.
He also spearheaded the strategic development and launch of a range of specialist cardiovascular products, and identified and established European marketing partnerships, before CVT was acquired by Gilead Sciences in 2009.
With a pharmaceutical career history spanning over two decades, Robin brings a wealth of knowledge and experience to Actelion UK from several managerial roles, which includes head of cardiovascular marketing at Sanofi-Synthélabo UK and marketing director within Bayer’s Global Strategic Marketing Group.
Robin commented: “This role attracted me from the very outset and I am privileged to have the opportunity to lead the UK team of such an innovative global pharmaceutical company.
“Actelion Pharmaceuticals is a science-based company committed to researching and developing treatments for rare orphan diseases in areas of high unmet clinical need such as pulmonary arterial hypertension, Gaucher’s and Niemann-Pick type C. I look forward to supporting Actelion’s continued commitment to these important therapy areas; to the specialist physicians, healthcare professionals and patient group communities”.
Actelion Pharmaceuticals UK is the British arm of Actelion Ltd, a biopharmaceutical company with its corporate headquarters based in Allschwil/Basel, Switzerland. Actelion Ltd focuses on the discovery, development and marketing of drugs for a high unmet medical need.
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
